Westlake Village BioPartners

Venture capital firm

Recent changes

  1. Feb 14, 2024Invested in Latigo Biotherapeutics (Series A, $135M) PR Newswire

Portfolio

1 total

Recent Investment Activity

1

Track record: led 1 and participated in 0 of 1 tracked venture round · led 1 Series A

DateCompanyEventRoleAmountValuationInvestorsSource
Feb 14, 2024Latigo BiotherapeuticsSeries ALed$135M—PR Newswire

Co-Investors

6

Similar Firms

overlapping sector, stage or region

Latest Pulse

  1. Latigo Sets Terms for a $272M Nasdaq IPOLatigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.→

Westlake Village BioPartners FAQ

What companies has Westlake Village BioPartners invested in?

Westlake Village BioPartners' portfolio includes Latigo Biotherapeutics.

Who does Westlake Village BioPartners co-invest with most?

In the rounds Value Add tracks, Westlake Village BioPartners most often invests alongside 5AM Ventures (1 shared deal), Ascenta Capital (1 shared deal), Blue Owl Capital (1 shared deal), Foresite Capital (1 shared deal), Qatar Investment Authority (1 shared deal).

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction